MedPath

Cascade Pharmaceuticals, Inc

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

9

Active:2
Completed:5

Trial Phases

2 Phases

Phase 1:6
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (66.7%)
Phase 2
3 (33.3%)

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

Phase 1
Completed
Conditions
Primary Biliary Cholangitis
Interventions
First Posted Date
2025-03-21
Last Posted Date
2025-07-11
Lead Sponsor
Cascade Pharmaceuticals, Inc
Target Recruit Count
24
Registration Number
NCT06888115
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

🇨🇳

The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

🇨🇳

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

Phase 1
Active, not recruiting
Conditions
MASH
Interventions
First Posted Date
2024-08-27
Last Posted Date
2025-04-30
Lead Sponsor
Cascade Pharmaceuticals, Inc
Target Recruit Count
104
Registration Number
NCT06573528
Locations
🇨🇳

Shanghai Xuhui Central Hospital, Shanghai, China

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects

Phase 1
Not yet recruiting
Conditions
MASH
Interventions
First Posted Date
2024-07-03
Last Posted Date
2025-02-26
Lead Sponsor
Cascade Pharmaceuticals, Inc
Target Recruit Count
80
Registration Number
NCT06485245
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Study of [14C]CS0159 in China Healthy Subjects

Phase 1
Completed
Conditions
Primary Biliary Cholangitis
Interventions
First Posted Date
2023-10-24
Last Posted Date
2023-11-21
Lead Sponsor
Cascade Pharmaceuticals, Inc
Target Recruit Count
6
Registration Number
NCT06098027
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Phase 2
Active, not recruiting
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Drug: 2mg CS0159
Drug: Placebo
First Posted Date
2023-06-09
Last Posted Date
2024-11-19
Lead Sponsor
Cascade Pharmaceuticals, Inc
Target Recruit Count
75
Registration Number
NCT05896124
Locations
🇨🇳

The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China

🇨🇳

Beijing Friendship Hospital, Captail Medcial University, Beijing, Beijing, China

🇨🇳

Beijing Youan Hostital, Captial Medical University, Beijing, Beijing, China

and more 13 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.